tirzepatide surmount-1 nejm 2022 weight loss percent Trial GLP-1 Weight Loss for Women:

2021 NEJM) reported constipation in 23.4% of semaglutide patients vs 9.5% on placebo Why its preferred on semaglutide: PEG works in the colon, not the stomach

Clinical Evidence and Expected Weight Loss Outcomes FDA-Approved Semaglutide Trial Data Clinical trial data for FDA-approved semaglutide provides context for expected outcomes: The STEP 1 trial showed an average weight loss of approximately 14.9% over 68 weeks when combined with reduced-calorie diets and increased physical activity

We focus on what works long-term to help patients lose weight

The potential risk of NAION must be weighed against the known benefits of these medications and the risks of untreated diabetes or obesity

In recent years, the landscape of weight loss treatment has shifted